ABSTRACT
Precise characterization of the hydrogen bond network present in discrete self-assemblies of benzene-1,3,5-tricarboxamide monomers derived from amino-esters (ester BTAs) is crucial for the construction of elaborated functional co-assemblies. For all ester BTA dimeric structures previously reported, ester carbonyls in the side chain acted as hydrogen bond acceptors, yielding well-defined dimers stabilized by six hydrogen bonds. The ester BTA monomer derived from glycine (BTA Gly) shows a markedly different self-assembly behaviour. We report herein a combined experimental and computational investigation aimed at determining the nature of the dimeric species formed by BTA Gly. Two distinct dimeric structures were characterized by single-crystal X-ray diffraction measurements. Likewise, a range of spectroscopic and scattering techniques as well as molecular modelling were employed to diagnose the nature of dynamic dimeric structures in toluene. Our results unambiguously establish that both ester and amide carbonyls are involved in the hydrogen bond network of the discrete dimeric species formed by BTA Gly. The participation of roughly 4.5 ester carbonyls and 1.5 amide carbonyls per dimer as determined by FT-IR spectroscopy implies that several conformations coexist in solution. Moreover, NMR analysis and modelling data reveal rapid interconversion between these different conformers leading to a symmetric structure on the NMR timescale. Rapid hydrogen bond shuffling between conformers having three (three), two (four), one (five) and zero (six) amide carbonyl groups (ester carbonyl groups, respectively) as hydrogen bond acceptors is proposed to explain the magnetic equivalence of the amide N-H on the NMR timescale. When compared to other ester BTA derivatives in which only ester carbonyls act as hydrogen bond acceptors, the fluxional behaviour of the hydrogen-bonded dimers of BTA Gly likely originates from a larger range of energetically favorable conformations accessible through rotation of the BTA side chains.
ABSTRACT
Glycosaminoglycans heparin and heparan sulfate are biologically active polysulfated carbohydrates that are among the most challenging biopolymers with regards to their structural analysis and functional assessment. Fragmentation of oligosaccharides and sulfate loss are important hindrance to their analysis by mass spectrometry (MS), requiring thus soft ionization methods. The recently introduced soft ionization method desorption electrospray ionization (DESI) has been applied here to heparin and heparan sulfate oligosaccharides, showing that DESI-MS is well suited for the detection of such fragile biomolecules in their intact form. Characterization of complicated oligosaccharides such as synthetic heparin octadecasulfated dodecasaccharide was successfully achieved. The use of water for a spray solvent instead of denaturing organic solvents allowed the first DESI-MS detection of noncovalent biomolecular complexes between heparin oligosaccharides and the chemokine Stromal Cell-derived Factor-1. The hyphenation of the DESI ion source with the high-resolution LTQ-Orbitrap MS analyzer led to high accuracy of mass measurement and enabled unambiguous determination of the protein-bound sulfated oligosaccharide.
Subject(s)
Chemokine CXCL12/metabolism , Heparin/chemistry , Heparin/metabolism , Heparitin Sulfate/chemistry , Heparitin Sulfate/metabolism , Spectrometry, Mass, Electrospray Ionization/methods , Animals , PolymerizationABSTRACT
1. This study investigated whether a single administration of a range of doses (1, 4 and 8 mg kg-1, i.p.) of paroxetine, citalopram or venlafaxine may simultaneously increase extracellular levels of 5-HT ([5-HT]ext) and noradrenaline ([NA]ext) by using in vivo microdialysis in the frontal cortex (FCx) of awake, freely moving Swiss mice. 2. In vivo, paroxetine induced similar increases in cortical [5-HT]ext at the three doses tested, and induced a statistically significant increase in cortical [NA]ext at 4 and 8 mg x kg-1. Citalopram increased neither [5-HT]ext nor [NA]ext at the lowest dose, but increased both neurotransmitter levels at 4 and 8 mg x kg-1. At these doses, citalopram induced greater increases in cortical [5-HT]ext than in [NA]ext. Venlafaxine increased [5-HT]ext and [NA]ext to about 400 and 140% of the respective basal values at 8 mg kg-1. 3. Citalopram and paroxetine have the highest potency to increase cortical [5-HT]ext and [NA]ext, respectively. In addition, the rank of order of efficacy of these antidepressant drugs to increase [5-HT]ext in vivo in the FCx of mice was as follows: venlafaxine>citalopram>paroxetine, while the efficacy to increase cortical [NA]ext in mice of paroxetine and citalopram is similar, and greater than that of venlafaxine. 4. In conclusion, extracellular levels of cortical [NA]ext increase with the highest doses of the very selective SSRI citalopram, as well as with the very potent SSRI paroxetine. Surprisingly, the SNRI venlafaxine increased cortical [5-HT]ext to a greater extent rather than [NA]ext in the range of doses studied in mice.
Subject(s)
Antidepressive Agents, Second-Generation/pharmacology , Frontal Lobe/drug effects , Norepinephrine/metabolism , Selective Serotonin Reuptake Inhibitors/pharmacology , Serotonin/metabolism , Animals , Citalopram/pharmacology , Cyclohexanols/pharmacology , Dose-Response Relationship, Drug , Frontal Lobe/metabolism , Male , Mice , Microdialysis , Paroxetine/pharmacology , Time Factors , Venlafaxine HydrochlorideABSTRACT
The role of serotonin (5-HT)1B receptors in the mechanism of action of selective serotonin re-uptake inhibitors (SSRI) was studied by using intracerebral in vivo microdialysis in conscious, freely moving wild-type and 5-HT1B receptor knockout (KO 5-HT1B) mice in order to compare the effects of chronic administration of paroxetine via osmotic minipumps (1 mg per kg per day for 14 days) on extracellular 5-HT levels ([5-HT]ext) in the medial prefrontal cortex and ventral hippocampus. Basal [5-HT]ext values in the medial prefrontal cortex and ventral hippocampus, approximately 20 h after removing the minipump, were not altered by chronic paroxetine treatment in both genotypes. On day 15, in the ventral hippocampus, an acute paroxetine challenge (1 mg/kg i.p.) induced a larger increase in [5-HT]ext in saline-pretreated mutant than in wild-type mice. This difference between the two genotypes in the effect of the paroxetine challenge persisted following chronic paroxetine treatment. Conversely, in the medial prefrontal cortex, the paroxetine challenge increased [5-HT]ext similarly in saline-pretreated mice of both genotypes. Such a challenge produced a further increase in cortical [5-HT]ext compared with that in saline-pretreated groups of both genotypes, but no differences were found between genotypes following chronic treatment. To avoid the interaction with raphe 5-HT1A autoreceptors, 1 micro m paroxetine was perfused locally through the dialysis probe implanted in the ventral hippocampus; similar increases in hippocampal [5-HT]ext were found in acutely or chronically treated wild-type mice. Systemic administration of the mixed 5-HT1B/1D receptor antagonist GR 127935 (4 mg/kg) in chronically treated wild-type mice potentiated the effect of a paroxetine challenge dose on [5-HT]ext in the ventral hippocampus, whereas systemic administration of the selective 5-HT1A receptor antagonist WAY 100635 did not. By using the zero net flux method of quantitative microdialysis in the medial prefrontal cortex and ventral hippocampus of wild-type and KO 5-HT1B mice, we found that basal [5-HT]ext and the extraction fraction of 5-HT were similar in the medial prefrontal cortex and ventral hippocampus of both genotypes, suggesting that no compensatory response to the constitutive deletion of the 5-HT1B receptor involving changes in 5-HT uptake capacity occurred in vivo. As steady-state brain concentrations of paroxetine at day 14 were similar in both genotypes, it is unlikely that differences in the effects of a paroxetine challenge on hippocampal [5-HT]ext are due to alterations of the drug's pharmacokinetic properties in mutants. These data suggest that there are differences between the ventral hippocampus and medial prefrontal cortex in activation of terminal 5-HT1B autoreceptors and their role in regulating dialysate 5-HT levels. These presynaptic receptors retain their capacity to limit 5-HT release mainly in the ventral hippocampus following chronic paroxetine treatment in mice.
Subject(s)
Membrane Transport Proteins , Nerve Tissue Proteins , Paroxetine/administration & dosage , Receptors, Serotonin/deficiency , Selective Serotonin Reuptake Inhibitors/administration & dosage , Serotonin/metabolism , Animals , Brain Chemistry/drug effects , Carrier Proteins/metabolism , Chromatography, High Pressure Liquid , Dialysis Solutions/analysis , Drug Administration Routes , Extracellular Space/chemistry , Extracellular Space/metabolism , Hippocampus/drug effects , Hippocampus/metabolism , Membrane Glycoproteins/metabolism , Mice , Mice, Knockout , Microdialysis , Oxadiazoles/administration & dosage , Paroxetine/analysis , Piperazines/administration & dosage , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Pyridines/administration & dosage , Receptor, Serotonin, 5-HT1B , Receptors, Serotonin/genetics , Serotonin/analysis , Serotonin Antagonists/administration & dosage , Serotonin Plasma Membrane Transport Proteins , TimeABSTRACT
Brain tumor cells secrete platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF-beta), and through local production of these growth factors, brain tumor cells may stimulate their own proliferation. Previously we have shown that several different clones of canine glioma cells secrete varying amounts of PDGF and TGF-beta which correlate with in vitro cloning efficiency and in vivo tumorigenicity. In this study, intracellular trafficking of PDGF and TGF-beta was assessed by treatment of each clone with agents preventing vesicular degradation and secretion of growth factors. Clone 2 was more sensitive to these agents (chloroquine and monensin) than clone 5, resulting in retention of intracellular 125I-PDGF and 125I-TGF-beta. Furthermore, exogenous TGF-beta inhibited DNA-synthesis dramatically in clone 2 (compared with clone 5), presumably by interfering with intracellular growth factor receptor availability. This is supported by the fact that exogenous TGF-beta increased the number of its receptors on clone 2 cells, whereas surface receptors decreased on clone 5 cells treated with TGF-beta. These results illustrate the potential for autocrine growth factors to interact with their receptors intracellularly during neoplastic cell proliferation.
Subject(s)
Brain Neoplasms/metabolism , Glioma/metabolism , Platelet-Derived Growth Factor/metabolism , Transforming Growth Factor beta/metabolism , Animals , Cell Division/physiology , Dogs , Receptors, Cell Surface/metabolism , Receptors, Transforming Growth Factor beta , Tumor Cells, CulturedABSTRACT
Merocyanine 540 (MC 540), a photosensitizing dye, has been used in preclinical studies and in a phase I clinical trial for the purging of leukemia, lymphoma, and neuroblastoma cells from bone marrow grafts. We evaluated MC 540 as an agent for the inactivation of brain tumor cell lines of medulloblastoma or glioma origin. The U373 glioma and 74SA medulloblastoma demonstrated significantly reduced survival as determined by in vitro clonogenic assay compared to normal glial cells when exposed to MC 540 and light. U87 glioma and Daoy medulloblastoma, however, were less sensitive than normal glial cells to MC 540 photoinactivation. In vivo injection of MC 540 into mice with malignant brain tumors disclosed greater dye incorporation into the malignant tissue compared with normal control mice brains or normal tissue surrounding the brain tumor. Increased uptake of MC 540 was observed in mice injected with either photosensitive (U373 and 74SA) or photoresistant (Daoy) cell lines. These data suggest that MC 540 may be an effective agent against certain brain tumors and that dye uptake in vivo does not reflect photosensitivity.
Subject(s)
Brain Neoplasms/pathology , Cell Division/drug effects , Cerebellar Neoplasms/pathology , Glioma/pathology , Medulloblastoma/pathology , Pyrimidinones/pharmacology , Radiation-Sensitizing Agents/pharmacology , Tumor Cells, Cultured/drug effects , Animals , Cell Line , Cell Survival/drug effects , Female , Flow Cytometry , Mice , Mice, Nude , Neoplasm Transplantation , Photochemotherapy , Rats , Tumor Stem Cell AssayABSTRACT
We measured 3H-thymidine incorporation by human brain tumor cell lines treated with varying doses of gallium nitrate. These DNA synthesis data indicate that the effects of gallium documented for brain tumor cell viability parallel those for alterations in DNA synthesis. The primitive, poorly-differentiated, small, round-cell tumors (medulloblastoma and rhabdomyosarcoma) appear to be more sensitive than glially differentiated neoplasms (glioblastoma) to DNA synthesis inhibition by gallium nitrate.
Subject(s)
Antineoplastic Agents/pharmacology , Brain Neoplasms/metabolism , DNA, Neoplasm/biosynthesis , Gallium/pharmacology , Glioma/metabolism , Medulloblastoma/metabolism , Rhabdomyosarcoma/metabolism , Brain Neoplasms/pathology , Cell Division/drug effects , Glioma/pathology , Humans , Medulloblastoma/pathology , Rhabdomyosarcoma/pathology , Thymidine , Time Factors , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolismABSTRACT
Gallium nitrate possesses antineoplastic activity against certain solid tumors; however, no studies exist regarding the effect of this metal on brain tumor cell proliferation. Several human brain tumor and rhabdomyosarcoma cell lines were incubated with increasing concentrations of gallium nitrate and cell proliferation was assessed by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. The growth of medulloblastoma 324, rhabdomyosarcoma TE671, and RD cells was markedly inhibited by gallium nitrate, while glioblastoma cell growth was only moderately inhibited (U373 cells) or actually stimulated (U87 cells). Gallium inhibited the cellular uptake of 59Fe; however, this block in 59Fe uptake was variable and closely paralleled the inhibitory effects of gallium on cell growth. Intracellularly, gallium may interfere with DNA synthesis by inhibiting ribonucleotide reductase. Such effects may be of relevance in the treatment of brain tumors with this metal.
Subject(s)
Antineoplastic Agents , Brain Neoplasms/pathology , Cell Division/drug effects , Gallium/pharmacology , Tumor Cells, Cultured/drug effects , Cell Line , Cerebellar Neoplasms/pathology , Dose-Response Relationship, Drug , Glioma/pathology , Humans , Medulloblastoma/pathology , Receptors, Transferrin/drug effects , Rhabdomyosarcoma/pathologyABSTRACT
Medulloblastoma is the most common malignant childhood brain tumor in which aggressive growth produces recurrence in approximately 50% of appropriately treated cases and metastases along the neuraxis in 30%. To date, no studies exist concerning the production of autocrine growth factors by this brain tumor type. Malignant brain tumors in adults often produce platelet-derived growth factor (PDGF). A medulloblastoma cell line, TE-671, has been used for many years in pediatric neuro-oncologic studies. We assayed this medulloblastoma cell line for the production of PDGF. PDGF is produced by medulloblastoma cells grown in monolayer tissue culture and stimulates PDGF-sensitive 3T3 fibroblasts to incorporate tritiated thymidine in a dose-dependent fashion. This biologic activity is blocked by PDGF antibodies in a dose-dependent relationship. We postulate that PDGF produced by medulloblastoma cells plays a role in the growth of this tumor by stimulating mitogenic activity.